The comparison of de novo BCR::ABL1+AML, CML-BP, 2017 ELN intermediate (n = 643) or adverse-risk (n = 863) BCR::ABL1 negative patients treated by intensive chemotherapy (DATAML registry) showed that patients with de novo BCR::ABL1+AML had a significant better outcome than 2017 ELN intermediate and adverse-risk patients (Table 3, Fig. 3). The gene discussed is BCR; the disease is acute myeloid leukemia.